Search Press releases Keywords From To 20 Nov 2024 UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa Read More 19 Nov 2024 Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Read More 18 Nov 2024 Transparency notification BlackRock, Inc. Read More 18 Nov 2024 Transparency notification BlackRock, Inc. Read More 14 Nov 2024 New BIMZELX[®] (bimekizumab-bkzx) data at ACR Convergence 2024 highlights UCB’s efforts to deliver differentiated care for patients with psoriatic arthritis and axial spondyloarthritis Read More 12 Nov 2024 Transparency notification BlackRock, Inc. Read More Pagination First page Previous page Previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Page 16 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
